Can a Compounding Pharmacy Make a Discontinued Drug? The Legal Answer Explained

Introduction: When Your Medication Disappears from the Market

Imagine a patient who has relied on the same medication for years. It manages a chronic condition, fits into a daily routine, and simply works. Then, without warning, the prescriber says the manufacturer has discontinued it. The pharmacy has no more, and there is no plan to make any. For that patient, an obvious question follows: can a compounding pharmacy make a discontinued drug?

The short answer is yes, a compounding pharmacy often can recreate a discontinued medication. But the legality depends entirely on one factor: why the drug was discontinued. Federal law draws a sharp line between drugs pulled from the market for safety or effectiveness reasons and drugs discontinued for business reasons. That single distinction determines everything.

Drug discontinuations are common. Manufacturers routinely exit markets because a product is no longer profitable, not because it is dangerous. When that happens, compounding can serve as a legal safety net. This article explains the regulatory framework in plain language, including Sections 503A and 503B of federal law and the FDA’s list of prohibited drugs under 21 CFR § 216.24, so patients and providers know exactly where they stand.

The One Question That Determines Everything: Why Was the Drug Discontinued?

The FDA and federal law recognize two fundamentally different types of drug discontinuation, and the difference is not a technicality. It decides whether compounding is even an option.

Safety-Based Withdrawal. Some drugs are removed from the market because they were found to be unsafe or ineffective. This includes drugs recalled after serious adverse events or those that failed post-market studies. These drugs carry an unacceptable level of risk, and the law treats them accordingly.

Commercial Discontinuation. Far more often, a manufacturer simply stops producing a drug for business reasons. The product may have low profitability, high manufacturing costs, a shifting market strategy, or supply chain challenges. There is no safety concern. The drug worked; it just stopped making financial sense to produce.

This is the dividing line. A drug withdrawn for safety reasons cannot be legally compounded. A drug discontinued for commercial reasons generally can be. The problem is that patients and providers often do not know which category applies to their medication. A knowledgeable compounding pharmacy can help determine this, frequently by checking the FDA’s formal tracking mechanism for safety-withdrawn drugs.

The FDA’s “Withdrawn or Removed List”: The Regulatory Boundary for Compounding

The FDA maintains an official list, codified at 21 CFR § 216.24, of drug products that may not be compounded because they were withdrawn or removed from the market for safety or effectiveness reasons. According to the Federal Register, drug products appearing on this list may not be compounded under the exemptions provided by Sections 503A and 503B.

This restriction applies to both traditional 503A pharmacies and 503B outsourcing facilities, with no exceptions. The list is maintained and updated by the FDA and is publicly available in the Code of Federal Regulations. Its purpose is straightforward: to prevent compounding pharmacies from recreating drugs that regulators determined pose real risks to patients.

If a drug is not on this list, that absence does not automatically make it compoundable, but it removes the single most significant legal barrier. There is also a secondary restriction to be aware of: the “difficult to compound” (DDC) list, which limits compounding of drugs that present significant technical challenges, regardless of why they were discontinued. As the Brookings Institution notes, both 503A pharmacies and 503B outsourcing facilities are prohibited from compounding products on either of these two lists. The current list structure was formalized in 2018, and the FDA continues to update it over time.

Understanding the 503A and 503B Compounding Framework

Federal law establishes two distinct legal pathways for compounding, each with different rules and levels of oversight. The legislative foundation is the Drug Quality and Security Act (DQSA) of 2013.

Congress passed the DQSA in direct response to a tragedy. In 2012, contaminated steroid injections from the New England Compounding Center (NECC) triggered a fungal meningitis outbreak that caused more than 750 infections and over 60 deaths. According to the U.S. Pharmacopeia, the DQSA clarified the FDA’s authority over compounding and reaffirmed USP’s role under Section 503A. The rigorous oversight that exists today is a direct result of that event.

503A: Traditional Compounding Pharmacies

503A pharmacies are state-licensed, traditional compounding pharmacies that prepare patient-specific medications based on individual prescriptions. To compound a discontinued drug under 503A, several conditions must be met:

1. A licensed pharmacist or physician must compound it.
2. It must be based on a valid, patient-specific prescription from a licensed prescriber.
3. Bulk drug substances must meet USP or National Formulary standards, or be components of FDA-approved drugs.
4. The drug must not appear on the Withdrawn or Removed List or the difficult-to-compound list.

These pharmacies are regulated primarily by state boards of pharmacy rather than directly by the FDA. They cannot produce large batches in advance; each compound must be tied to a specific patient prescription. Compounded drugs from 503A pharmacies are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality before they are dispensed.

503B: Outsourcing Facilities

503B outsourcing facilities are FDA-registered compounding facilities that can produce larger batches without patient-specific prescriptions. They are subject to Current Good Manufacturing Practice (CGMP) requirements, a higher standard than 503A. These facilities are typically relevant for hospitals, clinics, and healthcare systems that need larger quantities of a compounded medication.

503B facilities face the same prohibition on compounding drugs from the Withdrawn or Removed List. Both 503A and 503B operations must source active pharmaceutical ingredients (APIs) from FDA-registered facilities that meet USP or National Formulary standards.

What Cannot Be Compounded: Hard Legal Limits

To set accurate expectations, it helps to enumerate the absolute legal prohibitions.

1. Drugs on the Withdrawn or Removed List (21 CFR § 216.24). Pulled for safety or effectiveness reasons, these cannot be compounded under any circumstances.
2. Drugs on the “difficult to compound” (DDC) list. Prohibited regardless of why they were discontinued.
3. Biologics. As Frier Levitt explains, entire classes of drugs cannot be compounded, including biologicals. Federal law provides no legal pathway for marketing biologics outside an approved Biologics License Application (BLA). This is a hard stop.
4. Investigational drugs. Those still in clinical trials cannot be compounded.
5. Essentially copies of commercially available FDA-approved drugs. Under 503A, the compounded version must serve a legitimate, patient-specific need.

A current example of how the landscape can shift: in 2026, the FDA proposed formally excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, with a public comment period open through June 29, 2026. This signals the end of large-scale compounding of these GLP-1 agents. Notably, that situation involved a drug shortage, not a discontinuation. Most commercially discontinued drugs do not fall into any of these prohibited categories. For more on how this regulatory shift affects patients, see our detailed breakdown of semaglutide compounding pharmacy legal status in 2026.

When Compounding a Discontinued Drug Is Legally Permitted

Here is the affirmative case. When a drug was discontinued for commercial or business reasons and does not appear on any prohibited list, compounding is generally a legal and viable option.

Common scenarios include a manufacturer exiting a market due to low profitability, a drug being reformulated while the original is discontinued, or a niche medication losing enough commercial demand to justify mass production. As Applied Policy confirms, compounding can provide patients access to discontinued (but not formally discredited) therapies.

In these cases, a compounding pharmacy can replicate the active pharmaceutical ingredient, dosage form, and strength of the discontinued medication, and sometimes improve upon it by removing allergens or adjusting the delivery method. The prescriber plays a critical role. A documented clinical justification matters: if the prescriber documents that the compounded drug produces a “significant difference” for the identified patient, that strengthens the legal basis for compounding. Roughly 1% to 3% of all U.S. prescriptions are for compounded drugs, reflecting compounding’s well-established role in healthcare.

Step-by-Step: How to Access a Compounded Version of a Discontinued Drug

Accessing a compounded version of a discontinued medication is a collaborative process among the patient, the prescriber, and the compounding pharmacy. The following steps provide an actionable roadmap.

Step 1: Confirm Why the Drug Was Discontinued

Determine first whether the discontinuation was safety-based or commercial. Patients and providers can check the FDA’s Withdrawn or Removed List (21 CFR § 216.24) directly, or ask a knowledgeable compounding pharmacy to verify. The FDA’s drug database and the Federal Register are public resources for this research. If the drug was withdrawn for safety reasons, compounding is not a legal option, and alternative therapies should be discussed with the prescriber.

Step 2: Obtain a Valid Prescription from a Licensed Prescriber

A valid, patient-specific prescription is a legal requirement for 503A compounding. Patients should discuss the discontinued medication with their doctor or specialist and explain the clinical need. The prescriber should document the clinical justification, noting specifically why the compounded version is necessary (for example, no commercially available alternative, a specific dosage requirement, or an allergy to excipients in available alternatives). This documentation can be the difference between a pharmacy filling the prescription and declining it. Learn more about sending prescriptions to a compounding pharmacy and what to expect from the process.

Step 3: Choose a Reputable, Accredited Compounding Pharmacy

Look for PCAB accreditation, USP compliance (particularly USP 800 for hazardous drugs), FDA-registered API sourcing, and proper state licensure. Verify that the pharmacy ships to the patient’s state, since not all compounding pharmacies are licensed in every state. Ask the pharmacy directly whether it can compound the specific discontinued medication and what its verification process looks like. A quality pharmacy will proactively check the Withdrawn or Removed List before accepting the prescription.

Step 4: Work with the Pharmacy to Customize the Formulation

One major advantage of compounding is customization. The formulation can be tailored to the patient’s needs, including dosage form (capsule, cream, liquid, or troche), strength, and excipient profile. Allergens, dyes, gluten, lactose, and sugar can be removed. Delivery methods can be adjusted as well; a patient who cannot swallow tablets might receive the same active ingredient as a liquid or transdermal cream. Patients with known sensitivities may also benefit from working with a compounding pharmacy that specializes in allergy to medication ingredients.

Step 5: Understand Insurance Coverage and Cost

Insurance coverage for compounded medications is inconsistent. Many plans do not cover compounded drugs, requiring out-of-pocket payment. Patients should contact their insurance plan directly before proceeding. In some cases, a compounded version may cost less than alternatives, especially if the original was discontinued due to high manufacturing costs. Because many pharmacies do not publish prices, asking about cost upfront is advisable.

Why Compounding Pharmacies Matter: The Broader Context

Compounding is not a fringe service. The U.S. compounding pharmacy market was valued at approximately $6.45 billion in 2025 and is projected to reach $11.52 billion by 2035, driven by drug shortages, demand for personalized medicine, and an aging population. As of 2026, roughly 991 dedicated compounding pharmacy businesses operate in the U.S., with approximately 7,500 pharmacies offering advanced compounding services.

Drug shortages reinforce this role. The U.S. experienced a record 323 active drug shortages in the first quarter of 2024, declining to around 270 by April 2025. As PMC notes, compounding pharmacies are proving extraordinarily helpful during periods of drug shortages, discontinued medications, and high-cost FDA drugs. Compounding serves patients who fall through the gaps of mass-manufactured production: those with allergies, children who need palatable formulations, patients requiring precise dosing, and those whose medications were commercially discontinued. In September 2025, two pharmacist-legislators introduced the Drug Shortage Compounding Patient Access Act (H.R. 5316), further evidence of growing legislative recognition of compounding’s critical role.

How Nationwide Compounding Rx® Navigates This Complexity for Patients and Providers

Regulatory complexity is precisely why a knowledgeable compounding partner matters. Nationwide Compounding Rx® brings the expertise needed to navigate the legal nuances of discontinued drug compounding.

The pharmacy has maintained PCAB accreditation since its early days, operates a USP 800 compliant facility, and sources exclusively from FDA-inspected and cleared vendors. Its staff carries a combined 40 years of experience in pharmaceutical compounding, directly relevant to verifying whether a discontinued drug is legally compoundable. The pharmacy explicitly lists the ability to replicate discontinued medications as a core capability.

For patients who have lost access to a medication they depend on, speed matters. Nationwide Compounding Rx® offers a one to two business day turnaround on all medications and ships to 47 states plus Washington, D.C., making it accessible to most U.S. patients. The pharmacy works collaboratively alongside prescribers, supporting the documentation process described above, and can customize formulations by removing allergens, adjusting dosage forms, and offering multiple delivery methods.

Patients and providers can reach the pharmacy at 1-833-650-9836 or visit www.NationwideCompounding.com. Located in Scottsdale, Arizona, the pharmacy serves patients Monday through Friday, 7:00 a.m. to 3:30 p.m.

Frequently Asked Questions About Compounding Discontinued Drugs

Is a compounded version of a discontinued drug FDA-approved?
No. Compounded drugs are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality before they reach patients. Quality assurance depends on the compounding pharmacy, the prescribing clinician, and state regulatory oversight.

How do I know if my discontinued drug is on the FDA’s prohibited list?
A reputable compounding pharmacy can check 21 CFR § 216.24, or patients can search the FDA’s published list directly. If the drug was discontinued for business reasons and is not on the list, compounding is generally permitted.

Can a compounding pharmacy make a biologic that was discontinued?
No. Biologics cannot be compounded under either 503A or 503B. Federal law provides no legal pathway for this.

Will insurance cover a compounded version of a discontinued drug?
Coverage is inconsistent, and many plans do not cover compounded medications. Patients should contact their plan directly and ask the pharmacy about out-of-pocket costs before proceeding.

Can the compounded version differ from the original drug?
Yes, and often beneficially so. Compounding allows for removing allergens, adjusting dosage forms, and customizing strength to meet the patient’s specific needs.

Do patients need a new prescription if their medication was discontinued?
Yes. A valid, patient-specific prescription from a licensed prescriber is required for 503A compounding, and the prescriber should document the clinical justification for the compounded version.

Conclusion: A Legal Pathway Exists, But It Requires the Right Partner

Yes, a compounding pharmacy can make a discontinued drug, but only when the discontinuation was for commercial reasons rather than safety or effectiveness concerns, and only when no other legal prohibition applies. The governing framework includes the FDA’s Withdrawn or Removed List (21 CFR § 216.24), the 503A and 503B distinction, and the absolute prohibitions on biologics and difficult-to-compound drugs.

Navigating this landscape requires expertise from both the prescriber who documents clinical need and the compounding pharmacy that verifies legal permissibility. When compounding is permitted, it can restore access to a medication lost for purely commercial reasons, often with added customization benefits. As drug shortages and commercial discontinuations continue to affect patients, accredited compounding pharmacies like Nationwide Compounding Rx® play an increasingly important role, serving as the regulatory-savvy partner that patients and providers can trust.

Ready to Find Out If Your Discontinued Medication Can Be Compounded?

Losing access to a trusted medication is stressful, but a solution may be closer than expected. Patients and providers can contact Nationwide Compounding Rx® to discuss a specific discontinued medication and determine whether compounding is legally permitted.

Call toll-free at 1-833-650-9836 or visit www.NationwideCompounding.com. The pharmacy ships to 47 states plus Washington, D.C.; patients should verify that their state is covered. With a one to two business day turnaround, help can arrive quickly.

For prescribers: Healthcare providers are invited to contact the pharmacy directly to discuss compounding options for their patients, including formulation customization and clinical documentation support.

Backed by PCAB accreditation and full regulatory compliance, Nationwide Compounding Rx® offers the expertise and trust that navigating this complexity demands.